chufangao/CTO huggingface dataset:
Clinical trial NCT04576208: A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788
Official title: A Randomized Open-label Phase 2 Multicenter Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Receiving TAK-788
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Business Decision (no safety or efficacy concerns)
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-30
Primary completion date: 2022-07-31
Completion date: 2022-07-31
Plan to share individual participant data: YES
IPD sharing description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Clinical trial NCT04179110: Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor
Official title: A Phase II Trial of Pembrolizumab and Ramucirumab in Patients With Progressive Transitional Cell Carcinoma After Treatment With an Immune Checkpoint Inhibitor
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Funding was withdrawn prior to first enrollment.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-09-18
Primary completion date: 2022-12-15
Completion date: 2023-06-15
Plan to share individual participant data: NO
Clinical trial NCT05348681: A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS)
Official title: A Randomized, Double-blinded, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Hidradenitis Suppurativa
Sponsor: Aristea Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to safety findings in ongoing Phase 2 trials.
Enrollment: 25.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-07-18
Primary completion date: 2023-02-28
Completion date: 2023-02-28
Plan to share individual participant data: NO
Clinical trial NCT04079738: Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib
Official title: Phase I/II Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition of the Proteasome Inhibitor Ixazomib: Big Ten Cancer Research Consortium BTCRC-HEM17-092
Sponsor: Big Ten Cancer Research Consortium (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Funder requested termination due to halting internal development of TAK-659
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-09-20
Primary completion date: 2021-09-22
Completion date: 2022-02-23
Baseline population: There was one patient who had been eligible but never received treatment. The seven subjects who received active study treatment have been considered in this baseline analysis population.~This study was terminated due to Funder's decision during Phase I portion of the study.
Plan to share individual participant data: NO
Clinical trial NCT04407689: InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort
Official title: A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection in France and Belgium
Acronym: ILIAD-7-FR
Sponsor: Revimmune (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: poor accrual
Enrollment: 34.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-08
Primary completion date: 2022-03-30
Completion date: 2022-03-30
Plan to share individual participant data: NO
IPD sharing description: publication
Clinical trial NCT03339596: Effects of Erythropoietin for Cognitive Side-effects of ECT
Official title: Erythropoietin as an add-on Treatment for Cognitive Side-effects of Electroconvulsive Therapy
Acronym: EPO-T
Sponsor: Mental Health Services in the Capital Region, Denmark (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 60.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-06-26
Primary completion date: 2023-01-10
Completion date: 2023-02-10
Plan to share individual participant data: NO
Clinical trial NCT03468075: Gemcitabine Plus Ascorbate for Sarcoma in Adults
Official title: A Phase II Trial of Gemcitabine Plus High-Dose Ascorbate in Locally Advanced Unresectable or Metastatic Soft Tissue and Bone Sarcomas in Adults
Sponsor: University of Iowa (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Stopping rules met
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-07-11
Primary completion date: 2019-04-16
Completion date: 2020-10-19
Limitations and caveats: Study terminated early. Ten patients were enrolled in the first stage, and per protocol the study was terminated following interim analysis when 1 or fewer participants had a tumor response.
Plan to share individual participant data: NO
Clinical trial NCT04188301: Safety and Efficacy of IDA for Onchocerciasis
Official title: Safety and Efficacy of Combination Therapy With Ivermectin, Diethylcarbamazine, and Albendazole (IDA) for Individuals With Onchocerciasis
Acronym: DOLF IDA/Oncho
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 154.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-12-06
Primary completion date: 2022-03-14
Completion date: 2022-06-01
Limitations and caveats: Pause on clinical trial operations between March 2020 - June 2020 due to the COVID-19 pandemic. Decreased health and viability of the adult female worm population in participants may have reduced the study's ability to detect a significant macrofilaricidal effect of IDA. Study enrolled participants with light/moderate infections, which greatly decreased the risk of SAEs occurring. Future studies to assess tolerability of IDA would need to be conducted with higher infection rates.
Plan to share individual participant data: YES
IPD sharing description: Datasets used for published results will be shared publicly through a journal or other open source data repository so that the broader scientific community can access it. Only de-identified data will be shared publicly.
Clinical trial NCT05512494: Lot-to-lot Consistency of Quadrivalent Influenza Vaccine (Split Virion), Inactivated
Official title: A Randomized, Double-blind Clinical Trial to Evaluate Lot-to-lot Consistency , Immunogenicity and Safety of Quadrivalent Influenza Vaccine (Split Virion), Inactivated in Health Populations Aged 9~59 Years Old
Sponsor: Sinovac Biotech Co., Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 1260.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-11-27
Primary completion date: 2023-01-24
Completion date: 2023-01-24
Clinical trial NCT03393806: Repeat Dose Study of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD)
Official title: A Double Blind (Sponsor Open) Placebo-controlled, Stratified, Parallel Group Study to Evaluate the Efficacy and Safety of Repeat Doses of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD)
Sponsor: GlaxoSmithKline (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Recruitment was terminated early before meeting target enrolment due to a high screen failure rate and the feasibility of completing the study in a timely way
Enrollment: 17.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-04-18
Primary completion date: 2019-10-09
Completion date: 2020-01-06
Plan to share individual participant data: YES
IPD sharing description: IPD for this study will be made available via the Clinical Study Data Request site.
IPD time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.
IPD access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted when justified, for up to another 12 months.
Clinical trial NCT04464577: A Study to Evaluate the Effect of Fluconazole, Bupropion, or Itraconazole on the Drug Levels and Safety of BMS-986235
Official title: A Phase 1, Open-label Study to Evaluate the Effect of Fluconazole, Bupropion, or Itraconazole on the Pharmacokinetics and Safety of BMS-986235
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Business objectives have changed.
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-04-01
Primary completion date: 2021-06-07
Completion date: 2021-06-08
Clinical trial NCT03892525: Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma
Official title: Phase Ib Study Evaluating the Safety and Efficacy of Intratumoral Agonistic Anti-CD40 (Selicrelumab) in Combination With Anti-PDL1 (Atezolizumab) in Patients With Refractory or Relapsed B Cell Lymphoma
Sponsor: The Lymphoma Academic Research Organisation (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: End of drug development
Enrollment: 4.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-07-04
Primary completion date: 2021-04-07
Completion date: 2021-04-07
Plan to share individual participant data: NO
Clinical trial NCT03577899: Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)
Official title: A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects With Neovascular Age-Related Macular Degeneration (AMD) (PANDA-1)
Sponsor: Chengdu Kanghong Biotech Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: desired primary endpoint was not met
Enrollment: 1157.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-09-25
Primary completion date: 2020-09-25
Completion date: 2021-05-19
Plan to share individual participant data: NO
Clinical trial NCT03794973: Diabetes Autoimmunity Withdrawn in New Onset Patients (DAWN)
Official title: A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of TOL-3021 in Patients With New Onset Type 1 Diabetes Mellitus
Acronym: DAWN
Sponsor: Tolerion, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Modification to Clinical Development Plan
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-14
Primary completion date: 2021-12-14
Completion date: 2023-12-14
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04498403: A Study of the Long-Term Safety of Crisaborole Ointment, 2% in Japanese Pediatric and Adult Participants With Mild to Moderate Atopic Dermatitis
Official title: A PHASE 3, MULTICENTER, OPEN-LABEL STUDY OF THE LONG-TERM SAFETY OF CRISABOROLE OINTMENT, 2% IN JAPANESE PEDIATRIC AND ADULT PARTICIPANTS WITH MILD TO MODERATE ATOPIC DERMATITIS
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Terminated (This decision was made for business reasons only and is not related to any safety concerns regarding crisaborole.)
Enrollment: 40.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-09-14
Primary completion date: 2020-12-18
Completion date: 2020-12-18
Baseline population: Safety population included all participants who took at least 1 dose of study drug. Participants who entered the first Off-Treatment cycle were included.
Limitations and caveats: Participants were planned to be followed up to Week 56, however due to early termination of the study, participants were followed up to only Week 12.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT03179163: Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvessels in Humans
Official title: Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvascular Function and Vessel Remodeling in Hypertensive Humans
Acronym: H2SPharm
Sponsor: Penn State University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: COVID shut down human subjects research and then the grant funding expired
Enrollment: 10.0 (ACTUAL)
Number of arms: 4.0
Start date: 2016-07-20
Primary completion date: 2022-08-31
Completion date: 2022-12-31
Plan to share individual participant data: NO
Clinical trial NCT04147858: Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia
Official title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia
Sponsor: Aptinyx (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 310.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-11-12
Primary completion date: 2022-06-16
Completion date: 2022-06-16
Plan to share individual participant data: NO
Clinical trial NCT03792490: Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS
Official title: Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS
Acronym: ROCK-ALS
Sponsor: University Medical Center Goettingen (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 120.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-02-20
Primary completion date: 2022-11-30
Completion date: 2023-11-01
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04734860: Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 Symptoms
Official title: A Randomized, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 Symptoms
Sponsor: Sorrento Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: A different study will be conducted.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-30
Primary completion date: 2021-09-30
Completion date: 2021-11-30
Clinical trial NCT02763384: BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Official title: A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low accrual
Enrollment: 12.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-12-02
Primary completion date: 2022-02-11
Completion date: 2022-05-22
Plan to share individual participant data: NO
Clinical trial NCT04053062: LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer
Official title: A Phase I Study to Evaluate the Safety and Efficacy of PSMA-CART Co-expressing LIGHT in Treating Patients With Castrate-Resistant Prostate Cancer (CRPC)
Sponsor: Bioray Laboratories (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: SUSPENDED 
Why stopped: Due to efficacy evaluation
Enrollment: 12.0 (ESTIMATED)
Number of arms: 1.0
Start date: 2020-07-16
Primary completion date: 2022-05-15
Completion date: 2024-10-15
Clinical trial NCT04729205: Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Folfox in Patients With GI Malignancies
Official title: An Open Phase 1B Study for Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Oxaliplatin-based Chemotherapy in Patients With Gastro-intestinal Malignancies
Sponsor: Lipomedix Pharmaceuticals Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Investigational drug not available
Enrollment: 9.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-13
Primary completion date: 2023-09-10
Completion date: 2023-09-12
Plan to share individual participant data: NO
Clinical trial NCT04493320: 1/2-Dopaminergic Dysfunction in Late-Life Depression (The D3 Study)
Official title: 1/2-Dopaminergic Dysfunction in Late-Life Depression (The D3 Study)
Sponsor: New York State Psychiatric Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Study terminated by sponsor (NIMH)
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-10
Primary completion date: 2021-10-27
Completion date: 2021-10-27
Limitations and caveats: Data collected in the trial have been presented as required but are considered unreliable.
Plan to share individual participant data: NO
Clinical trial NCT04192110: Association of Diuretics With Change in Extracellular Volume, Natriuretic Peptides, Symptoms, and Cardiovascular Outcomes in CKD
Official title: Association of Diuretics With Change in Extracellular Volume, Natriuretic Peptides, Symptoms, and Cardiovascular Outcomes in CKD
Acronym: DOCK
Sponsor: VA Office of Research and Development (FED)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: The project has ended prior to beginning.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-08-11
Primary completion date: 2020-08-11
Completion date: 2020-08-11
Plan to share individual participant data: NO
Clinical trial NCT04325633: Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection
Official title: Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection
Acronym: ENACOVID
Sponsor: Assistance Publique - Hôpitaux de Paris (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Stop inclusions for insufficient recruitment
Enrollment: 30.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-24
Primary completion date: 2020-12-15
Completion date: 2020-12-15
Clinical trial NCT02516553: BI 894999 First in Human Dose Finding Study in Advanced Malignancies
Official title: An Open Label, Phase Ia/Ib Dose Finding Study With BI 894999 Orally Administered Once a Day in Patients With Advanced Malignancies, With Repeated Administration in Patients With Clinical Benefit
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 174.0 (ACTUAL)
Number of arms: 22.0
Start date: 2015-07-08
Primary completion date: 2021-11-23
Completion date: 2021-11-23
Baseline population: For Phase Ib - Schedule B SCLC, Phase Ib - Schedule B mCRPC, DMC decided on 28Nov2018 to lower the dose of SCLC and mCRPC due to safety concern, thus patients treated prior the decision received 2.5mg BI 894999 and patients treated after the decision received 2mg . For Phase Ib - Schedule C NC, the dose was lowered since DMC reclaimed the MTD as 6/3mg on 08Jul2020 after 1 patient already treated with 7/3.5mg, so the first patient in NC and all the following patients were treated with 6/3mg.
Limitations and caveats: This trial was closed in accordance with protocol-defined criteria for stopping the trial following assessments of futility. Trial was completed as described in protocol.
Plan to share individual participant data: YES
IPD sharing description: After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed Document Sharing Agreement.~Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.~The data shared are the raw clinical study data sets.
IPD time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
IPD access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.
Clinical trial NCT04517110: Perioperative Pregabalin for Reducing Opioid Consumption After Cardiac Surgery
Official title: Peri-Operative Pregabalin for Reducing opIoid Consumption AfTer Cardiac surgEry: A Randomized Trial
Acronym: OPIATE
Sponsor: Hamilton Health Sciences Corporation (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The COVID-19 pandemic has reduced recruitment such that the study is no longer feasible
Enrollment: 17.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-09
Primary completion date: 2022-09-07
Completion date: 2022-09-07
Plan to share individual participant data: NO
Clinical trial NCT04072380: A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataplexy
Official title: A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy
Acronym: SUVN-G3031
Sponsor: Suven Life Sciences Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 190.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-09-21
Primary completion date: 2023-06-07
Completion date: 2023-06-13
Plan to share individual participant data: NO
Clinical trial NCT02833766: Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer
Official title: Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer - A Multicenter Single Arm Phase II Trial
Sponsor: Swiss Group for Clinical Cancer Research (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: the trial was prematurely terminated as per SAKK board decision from 14th of November 2020. The trial is to be terminated after primary endpoint is reached.
Enrollment: 48.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-10-28
Primary completion date: 2020-10-31
Completion date: 2021-08-03
Plan to share individual participant data: NO